REFERENCES
1. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir 2012;52:245-66.
2. Pandey P, Steinberg GK. Neurosurgical advances in the treatment of moyamoya disease. Stroke 2011;42:3304-10.
3. Fujimura M, Tominaga T. Lessons learned from moyamoya disease: outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurol Med Chir 2012;52:327-32.
4. Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM, Marks MP, Steinberg GK. Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg 2009;111:927-35.
5. Kim SH, Choi JU, Yang KH, Kim TG, Kim DS. Risk factors for postoperative ischemic complications in patients with moyamoya disease. J Neurosurg 2005;103:433-8.
6. Ohue S, Kumon Y, Kohno K, Watanabe H, Iwata S, Ohnishi T. Postoperative temporary neurological deficits in adults with moyamoya disease. Surg Neurol 2008;69:281-6.
7. Jung YJ, Ahn JS, Kwon DH, Kwun BD. Ischemic complications occurring in the contralateral hemisphere after surgical treatment of adults with moyamoya disease. J Korean Neurosurg Soc 2011;50:492-6.
8. Fujimura M, Kaneta T, Mugikura S, Shimizu H, Tominaga T. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 2007;67:273-82.
9. Fujimura M, Shimizu H, Inoue T, Mugikura S, Saito A, Tominaga T. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[(123)I]iodoamphetamine single-photon emission computed tomography. Neurosurgery 2011;68:957-64;discussion 964-5.
10. Hayashi T, Shirane R, Fujimura M, Tominaga T. Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion. J Neurosurg Pediatr 2010;6:73-81.
11. Huang AP, Liu HM, Lai DM, Yang CC, Tsai YH, Wang KC, Yang SH, Kuo MF, Tu YK. Clinical significance of posterior circulation changes after revascularization in patients with moyamoya disease. Cerebrovasc Dis 2009;28:247-57.
12. Uchino H, Kuroda S, Hirata K, Shiga T, Houkin K, Tamaki N. Predictors and clinical features of postoperative hyperperfusion after surgical revascularization for moyamoya disease: a serial single photon emission CT/positron emission tomography study. Stroke 2012;43:2610-6.
13. Mukerji N, Cook DJ, Steinberg GK. Is local hypoperfusion the reason for transient neurological deficits after STA-MCA bypass for moyamoya disease? J Neurosurg 2015;122:90-4.
14. Fujimura M, Inoue T, Shimizu H, Saito A, Mugikura S, Tominaga T. Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease. Cerebrovasc Dis 2012;33:436-45.
15. Fujimura M, Tominaga T. Significance of cerebral blood flow analysis in the acute stage after revascularization surgery for moyamoya disease. Neurol Med Chir 2015;55:775-81.
16. Horie N, Morikawa M, Morofuji Y, Hiu T, Izumo T, Hayashi K, Nagata I. De novo ivy sign indicates postoperative hyperperfusion in moyamoya disease. Stroke 2014;45:1488-91.
17. Hamano E, Kataoka H, Morita N, Maruyama D1, Satow T1, Iihara K1, Takahashi JC. Clinical implications of the cortical hyperintensity belt sign in fluid-attenuated inversion recovery images after bypass surgery for moyamoya disease. J Neurosurg 2017;126:1-7.
18. Schaaf M, Mommertz G, Ludolph A, Geibprasert S, Mühlenbruch G, Das M, Krings T. Functional MR imaging in patients with carotid artery stenosis before and after revascularization. AJNR Am J Neuroradiol 2010;31:1791-8.
19. Amemiya S, Kunimatsu A, Saito N, Ohtomo K. Impaired hemodynamic response in the ischemic brain assessed with BOLD fMRI. Neuroimage 2012;61:579-90.
20. Qiao PG, Han C, Qian T, Li GJ, Yin H. BOLD-fMRI with median nerve electrical stimulation predict hemodynamic improvement after revascularization in patients with moyamoya disease. J Magn Reson Imaging 2017; doi: 10.1002/jmri.25598.
21. Hartkamp NS, van Osch MJ, Kappelle J, Bokkers RP. Arterial spin labeling magnetic resonance perfusion imaging in cerebral ischemia. Curr Opin Neurol 2014;27:42-53.
22. Goetti R, O'Gorman R, Khan N, Kellenberger CJ, Scheer I. Arterial spin labelling MRI for assessment of cerebral perfusion in children with moyamoya disease: comparison with dynamic susceptibility contrast MRI. Neuroradiology 2013;55:639-47.
23. Noguchi T, Kawashima M, Irie H, Ootsuka T, Nishihara M, Matsushima T, Kudo S. Arterial spin-labeling MR imaging in moyamoya disease compared with SPECT imaging. Eur J Radiol 2011;80:e557-62.
24. Bokkers RP, Bremmer JP, van Berckel BN, Lammertsma AA, Hendrikse J, Pluim JP, Kappelle LJ, Boellaard R, Klijn CJ. Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion. J Cereb Blood Flow Metab 2010;30:222-9.
25. Wang R, Yu S, Alger JR, Zuo Z, Chen J, Wang R, An J, Wang B, Zhao J, Xue R, Wang DJ. Multi-delay arterial spin labeling perfusion MRI in moyamoya disease -- comparison with CT perfusion imaging. Eur Radiol 2014;24:1135-44.
26. Qiao PG, Han C, Zuo ZW, Wang YT, Pfeuffer J, Duan L, Qian T, Li GJ. Clinical assessment of cerebral hemodynamics in Moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: a comparative study. J Neuroradiol 2017; doi: 10.1016/j.neurad.2016.12.006.
27. Uchino H, Nakayama N, Kazumata K, Kuroda S, Houkin K. Edaravone reduces hyperperfusion-related neurological deficits in adult moyamoya disease: historical control study. Stroke 2016;47:1930-2.
28. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 2010;81:673-8.
29. Fujimura M, Niizuma K, Inoue T, Sato K, Endo H, Shimizu H, Tominaga T. Minocycline prevents focal neurological deterioration due to cerebral hyperperfusion after extracranial-intracranial bypass for moyamoya disease. Neurosurgery 2014;74:163-70.
30. Sakamoto T, Kawaguchi M, Kurehara K, Kitaguchi K, Furuya H, Karasawa J. Risk factors for neurologic deterioration after revascularization surgery in patients with moyamoya disease. Anesth Analg 1997;85:1060-5.
31. Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100:142-9.
